Last $42.76 USD
Change Today 0.00 / 0.00%
Volume 36.3K
CNMD On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 1:17 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

conmed corp (CNMD) Snapshot

Open
$42.86
Previous Close
$42.76
Day High
$43.21
Day Low
$42.66
52 Week High
05/19/14 - $50.47
52 Week Low
08/30/13 - $30.86
Market Cap
1.2B
Average Volume 10 Days
141.8K
EPS TTM
$1.77
Shares Outstanding
27.2M
EX-Date
06/12/14
P/E TM
24.2x
Dividend
$0.80
Dividend Yield
1.75%
Current Stock Chart for CONMED CORP (CNMD)

conmed corp (CNMD) Related Bloomberg News

View More Bloomberg News

conmed corp (CNMD) Related Businessweek News

No Related Businessweek News Found

conmed corp (CNMD) Details

CONMED Corporation provides surgical devices and equipment for minimally invasive procedures and monitoring. It offers sports medicine products, including powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants, and related disposable products and fluid management systems; powered surgical instruments for use in large and small bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; electrosurgical generators and related instruments; and 2D and 3D video systems for use in minimally invasive orthopedic and general surgeries. The company also provides patient monitoring products comprising vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, ECG electrodes and cables, cardiac defibrillation and pacing pads, and blood pressure cuffs; surgical suction instruments and tubing products; and IV products used in critical care areas. In addition, it offers endomechanical instrumentation products, such as trocars, clip appliers, scissors, and surgical staplers used in the minimally invasive laparoscopic and gynecological surgery. Further, the company provides gastrointestinal and pulmonary products consisting of minimally invasive diagnostic and therapeutic products, including mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and polypectomy. Its products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The company operates in the United States, Canada, the United Kingdom, Japan, Australia, and internationally. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

3,600 Employees
Last Reported Date: 02/24/14
Founded in 1970

conmed corp (CNMD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $805.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $320.8K
Executive Vice President of Corporate Commerc...
Total Annual Compensation: $371.9K
Principal accounting Officer, Executive Vice ...
Total Annual Compensation: $316.9K
General Counsel and Executive Vice President ...
Total Annual Compensation: $290.6K
Compensation as of Fiscal Year 2013.

conmed corp (CNMD) Key Developments

Conmed Corporation Announces Quarterly Cash Dividend, Payable on July 7, 2014

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on July 7, 2014 to all shareholders of record as of June 16, 2014.

CONMED Corporation Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Second Quarter of 2014 and Reiterates Earnings Guidance for the Full Year of 2014

CONMED Corporation announced consolidated unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net sales of $181,941,000 compared with $187,014,000 for the same period a year ago. Income from operations was $17,308,000 compared with $15,870,000 for the same period a year ago. Income before income taxes was $15,847,000 compared with $14,241,000 for the same period a year ago. Net income was $8,626,000 or $0.31 per diluted share compared with $10,492,000 or $0.37 per diluted share for the same period a year ago. Net cash provided by operating activities was $17,025,000 compared with $5,472,000 for the same period a year ago. Purchases of property, plant, and equipment was $4,065,000 compared with $4,130,000 for the same period a year ago. Adjusted net income was $13,537,000 or $0.49 per diluted share compared with $12,859,000 or $0.45 per diluted share for the same period a year ago. Adjusted income from operations was $21,453,000 compared with $19,305,000 for the same period a year ago. Adjusted EBITDA was $33,360,000 compared with $32,068,000 for the same period a year ago. Total sales for the first quarter, a year-over-year decrease of 2.7%, primarily due to the lower capital product sales and adverse FX rates in this first quarter of the year. On a constant currency basis, this was comprised of an 8.9% decline in capital products and a 0.1% decrease, almost flat in single-use devices compared to the first quarter of last year. The decrease in capital products was largely due to lower sales of surgical visualization systems and within general surgery product lines, lower sales on electric surgery generators. The company provided earnings guidance for the second quarter of 2014 and reiterated earnings guidance for the full year of 2014. For the second quarter of 2014, the company anticipates sales will be in the range of $190 million to $195 million and adjusted earnings per share are forecasted to be in the range of $0.44 to $0.48. The company reiterates its full year 2014 sales guidance of $770 million to $780 million and full year adjusted diluted earnings per share guidance of $1.90 to $2.00. The company continues to expect that new product introductions and improving economic conditions will have a positive impact on sales throughout the remainder of 2014. For the remaining quarters of this year, the company anticipates a book tax rate of approximately 32% to 33%. The cash tax rate is less than the book tax rate. This year, the company anticipates a 15% to 20% cash tax rate.

CONMED Reportedly Mulls Sale

CONMED Corporation (NasdaqGS:CNMD) is exploring a sale and has contacted large medical device companies to gauge their buyout interest, according to people familiar with the matter. ConMed has reportedly asked Bank of America Merrill Lynch and Greenhill & Co Inc. to approach larger orthopedic device makers regarding a potential sale of the company. Shares of ConMed were up 6.3% at $44.89 on April 15, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CNMD:US $42.76 USD 0.00

CNMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cantel Medical Corp $35.71 USD +0.60
Integra LifeSciences Holdings Corp $47.53 USD +0.25
Masimo Corp $24.36 USD +0.33
NuVasive Inc $34.13 USD +1.12
Paramount Bed Holdings Co Ltd ¥3,120 JPY +10.00
View Industry Companies
 

Industry Analysis

CNMD

Industry Average

Valuation CNMD Industry Range
Price/Earnings 36.1x
Price/Sales 1.6x
Price/Book 2.0x
Price/Cash Flow 35.2x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONMED CORP, please visit www.conmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.